These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 35878870

  • 1. Polymer source affects in vitro-in vivo correlation of leuprolide acetate PLGA microspheres.
    Wan B, Bao Q, Wang R, Burgess DJ.
    Int J Pharm; 2022 Sep 25; 625():122032. PubMed ID: 35878870
    [Abstract] [Full Text] [Related]

  • 2. In vitro-in vivo correlation of PLGA microspheres: Effect of polymer source variation and temperature.
    Wan B, Bao Q, Burgess DJ.
    J Control Release; 2022 Jul 25; 347():347-355. PubMed ID: 35569590
    [Abstract] [Full Text] [Related]

  • 3. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.
    Andhariya JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, Burgess DJ.
    J Control Release; 2019 Aug 28; 308():1-13. PubMed ID: 31301338
    [Abstract] [Full Text] [Related]

  • 4. In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release.
    Andhariya JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, Burgess DJ.
    J Control Release; 2019 Nov 28; 314():25-37. PubMed ID: 31654687
    [Abstract] [Full Text] [Related]

  • 5. Effect of polymer source variation on the properties and performance of risperidone microspheres.
    Wan B, Bao Q, Zou Y, Wang Y, Burgess DJ.
    Int J Pharm; 2021 Dec 15; 610():121265. PubMed ID: 34748813
    [Abstract] [Full Text] [Related]

  • 6. Effect of polymer source on in vitro drug release from PLGA microspheres.
    Wan B, Andhariya JV, Bao Q, Wang Y, Zou Y, Burgess DJ.
    Int J Pharm; 2021 Sep 25; 607():120907. PubMed ID: 34332059
    [Abstract] [Full Text] [Related]

  • 7. Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation.
    Hirota K, Doty AC, Ackermann R, Zhou J, Olsen KF, Feng MR, Wang Y, Choi S, Qu W, Schwendeman AS, Schwendeman SP.
    J Control Release; 2016 Dec 28; 244(Pt B):302-313. PubMed ID: 27565212
    [Abstract] [Full Text] [Related]

  • 8. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J, Walker J, Ackermann R, Olsen K, Hong JKY, Wang Y, Schwendeman SP.
    Mol Pharm; 2020 May 04; 17(5):1502-1515. PubMed ID: 32074448
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.
    Shen J, Choi S, Qu W, Wang Y, Burgess DJ.
    J Control Release; 2015 Nov 28; 218():2-12. PubMed ID: 26423236
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of PLGA raw materials on in vitro and in vivo performance of drug-loaded microspheres.
    Liang D, Walker J, Schwendeman PS, Chandrashekar A, Ackermann R, Olsen KF, Beck-Broichsitter M, Schwendeman SP.
    Drug Deliv Transl Res; 2025 Jan 28; 15(1):185-202. PubMed ID: 38643259
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Donepezil accelerates the release of PLGA microparticles via catalyzing the polymer degradation regardless of the end groups and molecular weights.
    Quan P, Guo W, LinYang, Cun D, Yang M.
    Int J Pharm; 2023 Feb 05; 632():122566. PubMed ID: 36586633
    [Abstract] [Full Text] [Related]

  • 16. Long-acting PLGA microspheres: Advances in excipient and product analysis toward improved product understanding.
    Wan B, Bao Q, Burgess D.
    Adv Drug Deliv Rev; 2023 Jul 05; 198():114857. PubMed ID: 37149041
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An Accelerated Release Method of Risperidone Loaded PLGA Microspheres with Good IVIVC.
    Hu X, Zhang J, Tang X, Li M, Ma S, Liu C, Gao Y, Zhang Y, Liu Y, Yu F, Yang Y, Guo J, Li Z, Mei X.
    Curr Drug Deliv; 2018 Jul 05; 15(1):87-96. PubMed ID: 28521697
    [Abstract] [Full Text] [Related]

  • 19. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides.
    Sophocleous AM, Desai KG, Mazzara JM, Tong L, Cheng JX, Olsen KF, Schwendeman SP.
    J Control Release; 2013 Dec 28; 172(3):662-70. PubMed ID: 24021356
    [Abstract] [Full Text] [Related]

  • 20. Reverse Engineering the 1-Month Lupron Depot®.
    Zhou J, Hirota K, Ackermann R, Walker J, Wang Y, Choi S, Schwendeman A, Schwendeman SP.
    AAPS J; 2018 Oct 02; 20(6):105. PubMed ID: 30280294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.